Coming Soon: A Multi-Drug Cocktail for Hepatitis C | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Locteron Triumphs in Phase 2 Hepatitis C Trial

Back to News Homepage
Next

Hepatitis C Interim Study Results Favorable for TMC435

Coming Soon: A Multi-Drug Cocktail for Hepatitis C

The Editors at Hepatitis Central
November 8, 2010

Print this page

Similar to how AIDS is now treated, pharmaceutical and biotech companies are racing to come up with the optimal oral combination of drugs that can safely suppress Hepatitis C.

Bristol-Myers, Gilead Seek AIDS Cocktail Success in Hepatitis C

By Michelle Fay Cortez – Oct 29, 2010

Bristol-Myers Squibb Co. and Gilead Sciences Inc., makers of the top-selling combination pills for AIDS, are trying to duplicate their success to combat another evasive virus, hepatitis C.

The companies are among about a dozen that are developing drug cocktails more effective, less toxic and easier to take than current therapy. Hints of which blends may work will emerge next week, in research presented at a Boston meeting of the American Association for the Study of Liver Disease.

The pill combinations are designed to cure the liver- destroying hepatitis C virus without using interferon, a decades-old shot that causes a year of flu-like symptoms and works in only half of patients.

Continue reading this entire article:
http://www.bloomberg.com/news/2010-10-29/bristol-myers-gilead-seek-aids-cocktail-success-in-hepatitis-c.html

No Comments - be the first!
Share
Share
Previous

Locteron Triumphs in Phase 2 Hepatitis C Trial

Back to News Homepage
Next

Hepatitis C Interim Study Results Favorable for TMC435

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.